Table 2. Summary of the outcomes presented in this meta-analysis.

Group	No. of studies	No. of total patients	RR/HR (95% CI) (Gli1 positive VS Gli1 negative)	P for heterogeneity	I2	references
Histological grade	7	1374	1.20 (0.98, 1.47)	0.013	62.9%	[19, 24, 26, 28, 30–32]
T stage	7	1309	1.05 (0.87, 1.27)	0.051	52.1%	[19, 24, 26–28, 30, 32]
Clinical stage	3	735	1.04 (0.93, 1.18)	0.371	0.0%	[24, 26, 27]
Lymph node metastasis	8	1658	1.12 (0.92, 1.37)	0.000	75.9%	[19, 24, 26–28, 30–32]
ER	5	1366	1.03 (0.74, 1.42)	0.000	88.0%	[19, 26, 27, 32]
PR	4	1084	0.92 (0.70, 1.21)	0.000	83.8%	[19, 26, 27, 29, 32]
Her-2	3	880	1.12 (0.90, 1.39)	0.106	55.4%	[26, 27, 32]
DFS	4	1107	1.48 (1.14, 1.93)	0.038	64.5%	[8, 25, 31, 32]
3-year survival	6	1593	1.74 (1.28, 2.36)	0.278	20.6%	[8, 19, 25, 29, 31, 32]
5-year survival	6	1593	2.04 (1.62, 2.57)	0.482	0.0%	[8, 19, 25, 29, 31, 32]
OS	6	1593	2.10 (1.64, 2.68)	0.961	0.0%	[8, 19, 25, 29, 31, 32]